Literature DB >> 6784191

Selective inhibitors of platelet lipoxygenase: 4,7,10,13-eicosatetraynoic acid and 5,8,11,14-henicosatetraynoic acid.

T E Wilhelm, S K Sankarappa, M VanRollins, H Sprecher.   

Abstract

Nine acetylenic acids were evaluated to determine what structural features are required for selective inhibition of platelet lipoxygenase. Both 4,7,10,13-icosatetraynoic acid and 5,8,11,14-henicosatetraynoic acid inhibited the synthesis of 12-L-hydroxy-5,8,10,14-icosatetraenoic acid (HETE) more than 95 percent without significantly altering the production of either thromboxane B2 or 12-L-hydroxy-5,8,10-heptadecatrienoic acid (HHT). The ID50 concentrations (microM) for inhibiting the synthesis of thromboxane B2 and HETE were respectively 51 and 0.46 with 4,7,10,13-icosatetraynoic acid while similar concentrations of 64 and 0.31 were found for 5,8,11,14-henicosatetraynoic acid.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6784191     DOI: 10.1016/0090-6980(81)90150-7

Source DB:  PubMed          Journal:  Prostaglandins        ISSN: 0090-6980


  3 in total

Review 1.  12-lipoxygenase: a potential target for novel anti-platelet therapeutics.

Authors:  Jennifer Yeung; Michael Holinstat
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2011-07-01

2.  Potentiating effect of 5,8,11-eicosatrienoic acid on human platelet aggregation.

Authors:  M Lagarde; M Burtin; H Sprecher; M Dechavanne; S Renaud
Journal:  Lipids       Date:  1983-04       Impact factor: 1.880

3.  Enhancement of eicosaenoic acid lipoxygenation in human platelets by 12-hydroperoxy derivative of arachidonic acid.

Authors:  M Croset; M Lagarde
Journal:  Lipids       Date:  1985-11       Impact factor: 1.880

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.